Weiss Ratings Reaffirms "Sell (D-)" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

Key Points

• Weiss Ratings has reaffirmed its "sell (D-)" rating for Corvus Pharmaceuticals (NASDAQ:CRVS), indicating ongoing concerns about the company's stock performance.
• Despite the sell rating from Weiss, Wall Street Zen upgraded the stock from a "sell" to a "hold," suggesting varying perspectives on Corvus' potential among analysts.
• Corvus Pharmaceuticals reported a modest loss of ($0.10) EPS for the last quarter, exceeding market expectations of ($0.13), but analysts anticipate an EPS of -0.63 for the current fiscal year.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $13.00.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS traded up $0.13 during trading hours on Wednesday, reaching $7.00. The company's stock had a trading volume of 1,535,301 shares, compared to its average volume of 795,138. The stock has a market cap of $521.57 million, a PE ratio of -6.93 and a beta of 0.57. Corvus Pharmaceuticals has a fifty-two week low of $2.54 and a fifty-two week high of $10.00. The company's 50-day moving average is $5.71 and its two-hundred day moving average is $4.43.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03. Equities analysts expect that Corvus Pharmaceuticals will post -0.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Sowell Financial Services LLC acquired a new stake in Corvus Pharmaceuticals in the first quarter worth about $38,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at about $49,000. Sender Co & Partners Inc. acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at about $52,000. ProShare Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at about $54,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Corvus Pharmaceuticals by 20.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company's stock valued at $62,000 after acquiring an additional 2,599 shares during the last quarter. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.